Failure to Document Informed Consent for Restraints and Psychotropic Medications
Summary
The facility failed to provide evidence that residents and/or their representatives were informed of the risks, benefits, and available treatment options before restraints were initiated for two residents and before psychotropic medications were initiated for four residents. The report states that this deficient practice involved residents who were receiving wheelchair restraints or psychotropic medications without documentation that informed consent had been obtained or that the required discussions occurred before treatment began. For one resident with diagnoses including Alzheimer’s disease with behavioral disturbance, restlessness, and agitation, the record showed a general restraint consent signed on admission, a care plan for a push-button seatbelt in the wheelchair, and later a physician order for an alarming seatbelt restraint. The restraint evaluation documented agitation, frequent falls, and attempts to self-transfer, and noted that alternatives had been tried. However, the assessment only stated that the representative was notified and did not include documentation of consent or discussion of the risks and benefits of the specific restraint being used. During observation, the resident was in a wheelchair with an alarmed seatbelt and tab alarm in place and was unable to respond to questioning. For a second resident with diagnoses including Alzheimer’s disease, anxiety disorder, history of falling, depression, adjustment disorder, and stroke, the record showed a general restraint consent on admission, a care plan for a Velcro seatbelt in the wheelchair, and physician orders for bed and chair alarms and later a Velcro alarming seatbelt. The restraint evaluation documented that the resident forgot she could not walk and was at risk for falls, and that alternatives such as one-to-one activities and alarms had been tried. As with the first resident, the assessment stated that the representative was notified but did not document consent or discussion of the risks and benefits of the restraint. During observation, the resident was in a wheelchair with an alarm and seatbelt in place and was unable to respond to questioning. The report also identified four residents who received psychotropic medications without documentation of informed consent. One cognitively intact resident with vascular dementia, insomnia, anxiety, and major depression was receiving Abilify, Celexa, trazodone, temazepam, and desvenlafaxine, and the record contained nothing showing informed consent for any of these medications. Three other residents with severe cognitive impairment were receiving psychotropic medications as ordered: one received Cymbalta, haloperidol, and escitalopram; another received Risperdal for delusions in dementia; and the third also received Risperdal for delusions in dementia. Their records likewise contained nothing to indicate informed consent had been obtained. Staff interviews showed the DON and unit manager were unaware of informed consent requirements for psychotropic medications, and the facility policy required review of non-pharmacological alternatives, indications, risks and benefits, and the resident’s or representative’s right to accept or decline treatment before initiating or changing psychotropic medication.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.